Peptide IL-17 Capture Agents for Low-Abundance Cytokine Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies face challenges in detecting and quantifying the low abundance of IL-17A and IL-17F cytokines with high sensitivity, which are crucial for understanding disease progression and treatment efficacy, due to their low natural abundance and differences in receptor binding affinities.
Innovation Solution
Development of chemically synthesized capture agents, such as protein-catalyzed capture agents (PCC Agents), designed to bind specifically to IL-17A and IL-17F using iterative in situ click chemistry, with ligands targeting specific epitopes and labeled with detectable moieties for sensitive detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional sandwich immunoassays are used to detect IL-17A and IL-17F, then the detection method is well-established and reliable, but the sensitivity is insufficient due to the low natural abundance of these cytokines
Solution Approach 1:
The patent changes the chemical parameters of the detection system by using chemically synthesized capture agents with modified binding properties. These agents are designed with specific amino acid sequences that enhance affinity for IL-17A and IL-17F, allowing detection at lower concentrations. The synthesis methods enable precise control over the capture agent structure, optimizing binding parameters to overcome the low abundance problem.
Solution Approach 2:
The patent creates synthetic copies of natural binding proteins (capture agents) that replicate and enhance the binding function of antibodies. These chemically synthesized agents are designed to specifically bind IL-17A and IL-17F with high affinity, serving as improved copies that overcome the sensitivity limitations of traditional immunoassays while maintaining the fundamental binding mechanism.
2Measurement precision
If capture agents are designed to bind specifically to IL-17A and IL-17F using iterative in situ click chemistry, then the selectivity and sensitivity are improved, but the manufacturing complexity increases
Solution Approach 1:
The patent divides the capture agent synthesis into modular segments using iterative in situ click chemistry. Each synthesis cycle adds a specific functional module (binding domain, detectable moiety, linker) in a controlled manner. This segmented approach allows for systematic optimization of binding specificity and sensitivity while maintaining manageable manufacturing complexity through repeated use of the same chemical protocols.
Solution Approach 2:
The patent uses click chemistry reactions as intermediary steps in the synthesis process. These intermediary chemical reactions enable the controlled assembly of capture agent components with high specificity. The click chemistry methodology acts as a reliable mediator that connects different molecular fragments in a predictable and efficient manner, facilitating the creation of complex structures through standardized intermediate steps.
3Measurement precision
If chemically synthesized capture agents are used to detect low abundance cytokines, then the detection sensitivity is improved, but the cost and resource requirements increase
Solution Approach 1:
The patent designs capture agents that are chemically synthesized to be highly efficient and specific, reducing the total quantity needed for effective detection. The optimized binding properties allow smaller amounts of capture agent to achieve the same detection sensitivity, thereby reducing overall resource consumption. The self-optimizing nature of the synthesis methodology ensures that each molecule produced is highly functional, minimizing waste.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The capture agents enable sensitive and selective detection of IL-17A and IL-17F homodimers and heterodimers, providing insights into their roles in disease progression and treatment response.
Implementation Method 1
chemically synthesized capture agents (called protein-catalyzed capture agents, or PCC Agents) that are designed to bind to detect interleukin 17A (IL-17A) and interleukin 17F (IL-17F)
Data Source
AI summary
The present application provides stable peptide-based IL-17F and IL-17A capture agents and methods of use as detection agents. The application further provides methods of manufacturing IL-17F capture agents.